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Abstract 
Among cerebral creatine deficiency syndromes, GAMT deficiency can present the most severe 
symptoms, and is characterized by neurocognitive dysfunction due to creatine deficiency and 
accumulation of guanidinoacetate in the brain. So far, every patient was found with negligible 
GAMT activity. However, GAMT deficiency is thought under-diagnosed, in particular due to 
unforeseen mutations allowing sufficient residual activity avoiding creatine deficiency, but 
enough guanidinoacetate accumulation to be toxic. With poorly known GAA-specific 
neuropathological mechanisms, we developed an RNAi-induced partial GAMT deficiency in 
organotypic rat brain cell cultures. As expected, the 85% decrease of GAMT protein was 
insufficient to cause creatine deficiency, but generated guanidinoacetate accumulation causing 
axonal hypersprouting and decrease in natural apoptosis, followed by induction of non-apoptotic 
cell death. Specific guanidinoacetate-induced effects were completely prevented by creatine co-
treatment. We show that guanidinoacetate accumulation without creatine deficiency is sufficient 
to affect CNS development, and suggest that additional partial GAMT deficiencies, which may 
not show the classical brain creatine deficiency, may be discovered through guanidinoacetate 
measurement. 
Keywords 
Creatine; guanidinoacetate; creatine deficiency syndromes; GAMT deficiency; brain; 
development; RNA interference; adeno-associated virus. 
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Abbreviations : 
AAV : adeno-associated viruses; AGAT: arginine-glycine amidinotransferase; BBB : blood-
brain barrier; CNS: central nervous system; Cr : creatine; DAPI : 4',6-diamidino-2-phenylindole; 
EGFP : Enhanced Green Fluorescent Protein; GAA : guanidinoacetate; GABAAR : GABAA 
receptor; GAD : Glutamate Decarboxylase; GalC : Galactocerebroside; GAMT : 
guanidinoacetate methyltransferase; GAP43 : Growth-Associated Protein 43; GFAP : Glial 
Fibrillary Acidic Protein; GFP : Green Fluorescent Protein; 
1
H-MRS: proton-coupled magnetic
resonance spectroscopy; LC-MS/MS: liquid chromatography coupled to mass spectrometry in 
tandem; MAP2 : Microtubule-Associated protein 2; MBP : Myelin Basic Protein; MOI : 
multiplicity of infection; NeuN : Neuronal Nucleus protein; NFM : medium weight 
neurofilament; ORF : open reading frame; p-NFM : phosphorylated medium weight 
neurofilament; RNAi : RNA interference; ROC : rat hybridoma between olidodendrocytes and 
C6 astroglioma; scAAV : self-complementary AAV; shRNA : small hairpin RNA; SLC6A8 : 
creatine transporter; TUNEL : terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick 
end labeling. 
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Introduction 
Deficiency of guanidinoacetate methyltransferase (GAMT), creatine (Cr) synthesis second 
enzyme (gene GAMT), was the first identified cerebral creatine deficiency syndrome (Stöckler et 
al., 1994; Schulze et al., 1997; Braissant, 2014; Stöckler-Ipsiroglu et al., 2014). The two other 
creatine deficiencies are arginine:glycine amidinotransferase (AGAT; Cr synthesis first enzyme; 
gene GATM) (Item et al., 2001) and Cr transporter (gene SLC6A8) (Salomons et al., 2001) 
deficiencies. GAMT and AGAT deficiencies are autosomal recessive inherited metabolic 
diseases, while SLC6A8 deficiency is X-linked. Their hallmark is the virtual Cr absence when 
measured by 
1
H-MRS in cortex and basal ganglia. Central nervous system (CNS) is the main
tissue affected, with patients developing neurological symptoms in infancy, in particular 
intellectual disability/developmental delay and speech acquisition defects (Schulze, 2003). 
GAMT deficiency can present a wide variety of symptoms from mild forms to very severe 
neurological phenotypes (Mercimek-Mahmutoglu et al., 2006). Guanidinoacetate (GAA) 
accumulation upstream of the GAMT enzymatic block is thought to cause these severe 
phenotypes ranging from intractable epilepsies to autistic and automutilating behaviors as well as 
extrapyramidal syndrome (Schulze et al., 2001; Schulze, 2003). 
Unlike microcapillary endothelial cells at blood-brain barrier (BBB), surrounding astrocytes do 
not express SLC6A8, resulting in low Cr uptake efficiency and forcing the brain to complete its 
Cr needs by expressing AGAT and GAMT (Braissant et al., 2001; Béard and Braissant, 2010; 
Tachikawa and Hosoya, 2011; Braissant, 2012; Lowe et al., 2014). Under GAMT deficiency, 
cerebral Cr comes from periphery and the low BBB-crossing efficiency makes CNS Cr-deficient. 
Moreover, GAA accumulates in CNS (uptake from peripheral excess, endogenous AGAT 
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activity with no functional GAMT; Braissant, 2012). Despite low BBB Cr permeability, 
SLC6A8 expression in microcapillary endothelial cells allows high Cr dosage treatment of 
GAMT-deficient patients who nevertheless often remain with severe intellectual 
disability/developmental delay (Stöckler-Ipsiroglu et al., 2014). Few prenatally-diagnosed 
patients were treated pre-symptomatically and developed normally (Schulze and Battini, 2007; 
El- Gharbawy et al, 2013; Viau et al, 2013). 
 
GAMT deficiency is treatable, potentially under-diagnosed due to limited awareness, and was 
thus suggested as a newborn screening candidate through GAA measure (Mercimek-
Mahmutoglu et al., 2012; El-Gharbawy et al., 2013; Pasquali et al., 2014). All GAMT-deficient 
patients identified so far were diagnosed by 
1
H-MRS-measured brain Cr deficiency and showed 
negligible residual GAMT activity (Mercimek-Mahmutoglu et al., 2006, 2014; Stöckler-
Ipsiroglu et al., 2014; http://www.LOVD.nl/GAMT). Apart from identifying new patients with 
CNS Cr deficiency and negligible GAMT activity, newborn screening through GAA 
measurement may in addition identify GAMT-deficient patients with sufficient GAMT residual 
activity to escape diagnosis as Cr non-deficient, but sufficiently accumulating GAA to be toxic. 
Newborn screening may also identify other patients with levels of GAA altered independently of 
GAMT deficiency, as found recently for example for arginase deficiency (Amayreh et al., 2013). 
 
While mostly known for its ATP regeneration and buffering role (Wallimann et al., 1992; 
Brosnan and Brosnan, 2007), Cr was recently suggested to act also as neurotransmitter (Almeida 
et al., 2006; van de Kamp et al., 2013). Although of poorly known pathophysiology, Cr 
deficiency probably affects brain energy and neurotransmission. In CNS, GAA is toxic through 
GABAA receptor (GABAAR) activation which may explain its epileptogenic action (Neu et al., 
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2002), and disturbs energy through Na
+
-K
+
-ATPase/creatine kinase complex inhibition (Zugno et 
al., 2006). A Gamt
-/-
 mouse was developed showing the biochemical GAMT deficiency 
characteristics (Cr deficiency and GAA accumulation), which however does not present the 
patients severe neurological symptoms (Schmidt et al., 2004). 
 
To better understand GAA toxicity under GAMT deficiency on developing CNS, rat organotypic 
3D brain cell cultures were transduced by adeno-associated viruses (AAV) driving Gamt gene 
knock-down by RNA interference (RNAi). 
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Materials and Methods 
 
Selection of GAMT shRNAs 
Three 21nt siRNA sequences specific for rat Gamt ORF (genebank n°J03588) were selected 
according to the Wang and Mu (2004) algorithm and used to generate 66bp small hairpin RNA 
(shRNA)-encoding DNA inserts, later cloned into pRNAT-CMV3.2/Neo under cytomegalovirus 
(CMV) promoter (Genscript) (Figure 1A). GAMT-1, 2 and -3 shRNAs potential RNAi 
efficiency was evaluated by Dual Luciferase Assay by co-transfection of pRNAT-
CMV3.2/Neo/GAMT-1/2/3/empty with psiCHECK-GAMT (Promega; vector expressing GAMT 
ORF downstream of Renilla luciferase ORF) and a control firefly luciferase-expressing vector, 
into ROC cells (rat hybridoma between olidodendrocytes and C6 astroglioma) plated at 80% 
confluence using jetPEI reagent (Polyplus). Cells were washed and lysed after 48h with lysis 
buffer, and cell extract was measured by Dual Luciferase Assay (Promega) using a TD-20/20 
luminometer (Turner Designs). Renilla luciferase activity was normalized with firefly luciferase 
activity. GAMT-2 shRNA presented the highest RNAi potential, with 81% decrease of Renilla 
luciferase activity (Figure 1B). pRNAT-CMV3.2/Neo/GAMT-2, mismatched and scrambled 
controls were used to demonstrate the specific GAMT knock-down. After 24h, stably transfected 
ROC cells were selected with 300 g/ml neomycin. Cells were harvested 6 days after 
transfection and their GAMT protein level was quantified by western blotting (Figure 1C). 
 
Adeno-associated virus production 
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Several AAV genotypes/serotypes were tested to uncover the most efficient vector for 
developing our GAMT deficiency model in immature brain cells (Tenenbaum et al., 2004): 
AAV2,2/1,2/5,2/8 (single-stranded) and scAAV2,2/5,2/8,2/9 (self-complementary) with 
multiplicity of infection (MOI) of 100, 300 and 1000 viral genomes per cell (data not shown). 
AAV2 and scAAV2 proved to be the most efficient in our cultures, where they were able to 
target neurons, astrocytes and oligodendrocytes (Figure 2A). GAMT RNAi-expressing AAV2 
viruses were prepared by cloning GAMT-2 shRNA and its mismatched and scrambled controls 
into pAAV-hrGFP (Agilent Technologies) under CMV promoter (pAAV-hrGFP/GAMT-
2/mismatched/scrambled). pAAV-hrGFP co-expresses hrGFP, also under CMV promoter, for the 
follow-up of transduced cells. AAV2/GAMT-2/mismatched/scrambled viruses were prepared 
with AAV-293 cells and the Agilent AAV Helper Free system, according to supplier instructions 
(Agilent Technologies). Viral particles were purified with the AAV Purification Virakit 
according to manufacturer instructions (Virapur) and stored at -20°C until use. Titration of total 
AAV2 particles (empty and full viruses) was performed with the AAV2 Titration ELISA 
(Progen Biotechnik GMBH) according to manufacturer instructions, using a Nanodrop 2000c at 
450 nm (Thermo Fisher Scientific). Titration of efficient AAV2 particles was performed by 
qPCR. Purified AAV2/GAMT-2/mismatched/scrambled were obtained with titers of 10
10
. Self 
complementary AAV2 (scAAV2) viruses transducing GAMT RNAi were customized under the 
construction ITR-(U6 promoter)-(GAMT-2/mismatched/scrambled)-(CMV promoter)-EGFP-
PolyA-ITR (SignaGen). EGFP allowed the follow-up of transduced cells. Purified 
scAAV2/GAMT-2/mismatched/scrambled were obtained with titers of 10
12
-10
13
 (SignaGen). 
AAV2/GAMT-2 particles were used to transduce ROC cells (MOI: 300) to validate the AAV2-
transduced Gamt knock-down by GAMT-2 shRNA (Figure 1C), while scAAV2/GAMT-
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2/mismatched/scrambled viruses were used to generate a GAMT deficiency model by 
transduction of GAMT-2 shRNA in 3D organotypic developing brain cell cultures in aggregates 
(Figure 1D).   
 
3D organotypic cultures of developing brain cells 
Pregnant rats (Sprague-Dawley 300g, Charles River) were handled according to the Swiss 
Academy for Medical Science rules. Their embryos were dissected out at E15.5 day to prepare 
3D primary cultures of brain cells in aggregates from their mechanically-dissociated whole 
brains, as previously described (Braissant et al., 2002). Aggregates develop with neurons, 
astrocytes and oligodendrocytes organized in a 3D network acquiring a tissue-specific pattern 
resembling that of the in vivo brain, and are therefore considered as organotypic brain cell 
cultures (Figure 2A). They express AGAT, GAMT and SLC6A8 in the same manner as the in 
vivo brain and synthesize their own Cr, suggesting that they behave as in vivo CNS for Cr 
synthesis and transport (Braissant et al., 2001, 2008, 2010). They are grown under continuous 
gyratory agitation (80 rpm) in a serum-free, Cr-free and chemically-defined medium, in which 
precursor amino acids for GAA and Cr synthesis (Arg, Gly and Met) are provided by the DMEM 
amino acid mix used. To generate RNAi-driven Gamt knock-down, cultures were infected at day 
in vitro 0 (DIV0) by either AAV2 or scAAV2 vectors co-transducing GFP (AAV2) or EGFP 
(scAAV2) expression and a specific GAMT/mismatched/scrambled shRNA with MOI of 100, 
300 or 1000. Additional cultures were treated, from DIV 5 on, with a final concentration of 10 or 
30 µM GAA at every medium change until harvest to verify GAA specific effects. Co-treated 
cultures were supplemented with 1 mM Cr with every media change until harvest. Aggregates 
were harvested at DIV8, 18 and 28. Aggregate pellets were collected by sedimentation, three 
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rapid rinsing with cold PBS, and either frozen in liquid nitrogen for metabolite (liquid 
chromatography coupled to tandem-mass spectrometry, LC/MS-MS) and protein (western 
blotting) analysis, or embedded in cryo-medium (Tissue-Tek O.C.T., Digitana) and frozen in 
liquid nitrogen-cooled isopentane for immunohistological analysis. Samples were kept at -80°C 
until use. Culture medium was also harvested at DIV8, 18 and 28 and kept at -80°C for 
metabolite analysis by LC/MS-MS. 
 
Measure of creatine and guanidinoacetate 
Cr and GAA determination in 3D cultures was performed by LC/MS-MS, as described in details 
(Braissant et al., 2008). For intracellular measure, aggregates were homogenized in 0.1 % (v/v) 
formic acid in H2O at 4°C using a FastPrep Cell Disrupter F120 (Qbiogene) and centrifuged at 
10'000 g for 5 min at 4°C. To 20 l of the supernatant were successively added 5 l of 10 M d3-
Cr (CDN Isotopes) and 10 M 13C2-GAA (CDN Isotopes) as internal standards, 171 l H2O and 
4 l formic acid (98-100 % w/v). For extracellular measure, 20 µl of culture medium were used. 
Cr and GAA were purified by micro-solid phase extraction (Oasis MCX Elution Plate, Waters). 
Separation of Cr and GAA was achieved at 30°C using an ACQUITY® UPLC BEH HILIC 
silica 2.1x50mm 1.7m column (Waters). The colum flow rate was 300 µl/min and the mobile 
phases consisted of acetonitrile, H2O and 200 mmol/l ammonium formate pH 3.2. The column 
effluent was monitored using a Triple Quadrupole TSQ Quantum Discovery (Thermo Scientific). 
The instrument was equipped with an electrospray interface and controlled by the Xcalibur 
software (Thermo Scientific). Samples were analyzed in positive ionization mode operating in a 
cone voltage of 4kV. The tandem mass spectrometer was programmed using the selected 
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reaction monitoring mode (SRM) to allow the [MH
+
] ions of Cr and GAA respectively at m/z 
132 and 118 and that of the internal standards D3-Cr and 
13
C2-GAA at m/z 135 and 120 to pass 
through the first quadrupole (Q1) and into the collision cell (Q2). The daughter ions for Cr and 
GAA were of m/z 90 and 76 respectively, and of m/z 93 and 78 for D3-Cr and 
13
C2-GAA 
respectively. Calibration curves were computed using the ratio of the peak area of the analytes 
and internal standard using a weighted (1/x
2
) least squares linear-regression analysis. 
 
Antibodies, western blotting and immunohistochemistry 
The GAMT protein was detected with an affinity-purified rabbit polyclonal antibody previously 
developed in our laboratory and used with a 1:1000 concentration (Braissant et al., 2005). All the 
other primary antibodies used in this study are commercially available, as follows: GalC (1:100, 
MAB5254), GFAP (1:100/1:5’000, MAB 360), MAP-2 (1:100, MAB378), NeuN (1:100, 
MAB377), p-NFM (clone NN18, 1:100, MAB5254) and GABAAR (1:100/1:500, MABN489, 
targeting the 1 subunit of GABAAR) mouse monoclonal and GAP43 (1:100/1:20’000, AB5220) 
rabbit polyclonal (Chemicon); β-tubulin (1:1’000, T8578) mouse monoclonal (Sigma-Aldrich); 
Actin (1:1’000, sc1616), MBP (1:500, sc13914) and GAD (1:100/1:500, sc7513) goat 
polyclonal; NFM (clone NF-09, 1:1’000, sc51683) mouse monoclonal (Santa Cruz 
Biotechnology); cleaved caspase-3 (1:200, 9664) and caspase-3 (1:1’000, 9665) rabbit 
monoclonal (Cell Signaling Technology). Secondary antibodies were horse radish peroxidase-
conjugated goat anti-mouse, anti-rabbit or rabbit anti-goat IgG (Vector laboratories) for western 
blotting, and goat anti-mouse, anti-rabbit or donkey anti-goat IgG labeled with Alexa Fluor® 
555 (red) (Life Technologies). 
 
12 
 
For western blotting, brain cell aggregates or ROC cells were homogenized in 150 mM NaCl, 50 
mM Tris-HCl, pH 8.0, 1% NP-40 (Sigma-Aldrich) and Protease Inhibitor Cocktail - Complete 
Mini (Roche), sonicated and centrifuged. The supernatant was harvested and protein dosage was 
performed by bicinchoninic acid assay (Thermo Scientific). Samples were prepared with a final 
concentration of 1 µg/µl in NuPAGE
®
 LDS Sample Buffer and resolved on NuPAGE
®
 4-12% or 
12% Bis–Tris gels using NuPAGE® MOPS SDS Running Buffer (Life Technologies) at a 
constant voltage (200 V, 60 min). Protein transfer was then performed on nitrocellulose 
membranes (Millipore) for 1h at 100 V. Membranes were washed in TBS/Tween (20 mM 
Trizma base, 137 mM NaCl, 0.05% Tween, pH 7.6) and blocked in 5% non-fat dry milk in TBS-
Tween for 1h at RT. Membranes were incubated with primary antibodies (see above) diluted in 
3% dry milk and TBS-Tween, O/N at 4°C. Membranes were probed with horse radish 
peroxidase-conjugated secondary antibodies (see above) diluted 1:3000 in 3% dry milk and TBS-
Tween, 2h at RT, then developed by chemiluminescence (ECL Western Blotting Detection 
Reagents, GE Healthcare). Blots were stripped (ReBlot Plus Mild Antibody Stripping Solution, 
Millipore) and re-probed with antibody against -tubulin or actin as loading control. Images 
were taken with a Luminescent Image Analyzer LAS-4000 (Fujifilm, Life Science) and 
quantified with the public Java-based image processing program ImageJ (National Institutes of 
Health). Data were acquired in arbitrary densitometric units and transformed to percentages of 
the densitometric levels of control samples visualized on the same blots. 
 
For immunohistochemistry, 16 μm cryosections of aggregates were fixed 1h in 4% 
paraformaldehyde in PBS at RT. Non-specific antibody binding sites were blocked 1h at RT with 
1% bovine serum albumin (BSA; Sigma-Aldrich) in PBS (BSA-PBS). Primary antibodies diluted 
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1:100 in 1% BSA-PBS where applied to sections O/N at 4°C, then detected with appropriate 
fluorescent secondary antibodies (1:100, 2h RT) labeled with Alexa Fluor® 555 (see above). 
Tyramide Signal Amplification (TSA, Molecular Probes) was used to amplify the detection 
signal of cleaved caspase-3, according to supplier recommendations. Sections were mounted 
under FluorSave Reagent (Calbiochem) and observed using an Olympus BX50 microscope 
equipped with appropriate filters for red, green and blue fluorescence. Stained sections were 
digitized with a UC30 digital camera mounted on the microscope, allowing image processing 
and merging with the Cell Sens Imaging Software (Olympus). 
 
Evaluation of cell death 
Cell death in our cultures was evaluated through three different techniques. Apoptosis was 
evaluated by western blotting and immunohistochemitry for activated cleaved caspase-3 (red 
fluorescence). Cryosections stained for cleaved caspase-3 were co-labeled by terminal 
deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL, green 
fluorescence, Roche Applied Science) and nuclear 4',6-diamidino-2-phenylindole  (DAPI, blue 
fluorescence, Life technologies) staining according to suppliers recommendations, in order to 
evaluate the proportions of apoptotic and non-apoptotic cell deaths. 
 
Evaluation of GAMT RNAi specificity in 3D organotypic brain cell cultures 
GAMT RNAi specificity in 3D brain cell cultures was analyzed by the use of negative controls, 
evaluation of off-target effects, as well as direct GAA exposure and Cr rescue experiments. 
Empty scAAV2 vectors (i.e. expressing EGFP but not transducing any shRNA), as well as 
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scAAV2 vectors transducing specific mismatched and scrambled controls for GAMT-2 shRNA, 
were used as negative controls, always with the maximal MOI of 1000. Using these negative 
controls, no significant effect on GAMT protein expression or Cr and GAA levels could be 
observed. The mismatched control, having 2 mutations in the middle of the GAMT-2 siRNA 
sequence and thus showing very similar hybridization properties, allowed evaluation of off-target 
effects. scAAV2/mismatched-transduced cultures showed no significant differences as compared 
to control or scAAV2/empty-transduced cultures. In particular, no significant effect on culture 
growth, brain cell morphologies or death were observed, nor on the expression of genes involved 
in cytoskeleton (NFM, p-NFM, MAP2, GFAP, actin, -tubulin), myelin sheath (MBP), 
neurotransmission (GAD, GABAAR) or apoptosis (caspase-3). The specificity of GAA effects 
under GAMT RNAi was verified by direct exposure to 10 and 30 M GAA, which resumes the 
effects of scAAV2-transduced GAMT RNAi. Finally, rescue experiments by Cr co-treatment (1 
mM) prevented every effect of GAMT RNAi, or of direct GAA exposure, observed in this study, 
in particular by preventing GAA accumulation despite GAMT deficiency. This demonstrated 
that every RNAi-driven effect observed in this study were specifically due to GAA accumulation 
(Figures 3-7). 
 
The only non-specific effect shown in this study was due to scAAV2 vectors, and not to RNAi. 
Indeed, scAAV2 drove a non-specific reactive effect in 3D brain cell cultures that was 
observable only on the long term (DIV28), in particular by reactive astrocytes (GFAP increase), 
slowing of oligodendrocyte differentiation (MBP decrease but stability of GalC) and decrease of 
NFM (Figures 4,5). 
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Statistical analysis 
All data points are expressed as mean ± standard error of the mean (SEM). Statistical 
significance of the differences between various conditions was determined by Student’s t-test 
(one way analysis of variance); p<0.05 was considered significant. Data from 3D organotypic 
brain cell cultures are representative of more than 5 independent culture settings, each performed 
with n=6 for each conditions. Within these culture settings: Cr/GAA measurements by LC/MS-
MS representative of 3 independent experiments, evaluated with n=6 for each conditions; 
histological data representative of 4 independent experiments, evaluated with n=3 for each 
conditions; western blotting representative of 4 independent experiments, evaluated with n=3 for 
each conditions. 
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Results 
 
scAAV2-transduced GAMT deficiency in developing brain cells 
Three rat Gamt open reading frame (ORF)-specific sequences were selected (Figure 1A) and 
used in GAMT-expressing ROC cells to evaluate their RNAi potential by dual luciferase assay. 
Maximal RNAi was obtained by GAMT-2 shRNA (-80%; Figure 1B). RNAi specificity was 
analyzed by ROC cells transfection with pRNAT-CMV3.2/Neo/GAMT-2, 
mismatched/scrambled controls (Figure 1A) and empty vectors. GAMT-2 shRNA led to a 85% 
GAMT protein decrease (Figure 1C). GAMT expression after empty/mismatched/scrambled 
transfections was not significantly different from untransfected cells. 
 
Having determined the best interfering sequence in nerve cell monolayer (Figure 1A-C), our 
next goal was choosing the best AAV to maximize 3D brain cell cultures transduction (Figure 
2A,B). Many serotypes exist with transduction efficacy depending on cellular tropism and 
models used. Therefore, several genotypes/serotypes were tested (AAV2,2/1,2/5,2/8; 
scAAV2,2/5,2/8,2/9) with MOI of 100, 300 and 1000, uncovering the most efficient for our 
model. AAV exposure was initiated at DIV0 to maximize infection before cell aggregation. 
AAV2/scAAV2 proved to be the best (data not shown), and transduced neurons, astrocytes and 
oligodendrocytes as shown by Enhanced Green Fluorescent Protein (EGFP) expression 
observable from DIV5 to 28, co-labeled with Neuronal Nucleus protein (NeuN), Glial Fibrillary 
Acidic Protein (GFAP) and Galactocerebroside (GalC) respectively; Figure 2B). AAV2-driven 
GAMT-2 shRNA expression was tested in ROC cells (MOI: 300) leading to 75% GAMT protein 
decrease (Figure 1C). 
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To generate a GAMT-deficient model in developing CNS, scAAV2/GAMT-
2/mismatched/scrambled were transduced in 3D organotypic brain cell cultures (Figure 1D,E). 
MOIs 100/300/1000 were tested, except for mismatched/scrambled which received MOI 1000 
only. The GAMT protein decrease was significant, maximal and attenuated at DIV8, 18 and 28, 
respectively (-37±9%; -85±10%; -50±14%; MOI 1000) (Figure 1D).  At DIV8, controls 
expressed low GAMT levels (6% of DIV18; Figure 1E), and mild RNAi was observed (-46%). 
Maximal GAMT levels were observed in DIV18 controls, in which knockdown was as efficient 
as -94% in this representative culture (Figure 1E). GAMT was less expressed at DIV28 (78% of 
DIV18; Figure 1E), where a maximal -75% knockdown was induced. 
 
No creatine deficiency but guanidinoacetate accumulation under partial GAMT deficiency 
Despite significant GAMT protein knockdown at DIV8 (-37%), DIV18 (-85%) and DIV28 (-
50%) (Figure 1D), no Cr deficiency was observed in scAAV2/GAMT-2-transduced cultures. Cr, 
analyzed by liquid chromatography coupled to mass spectrometry in tandem (LC-MS/MS), was 
measured intracellularly at 61±6 versus 75±14 nmol*mg prot-1 in controls versus 
scAAV2/GAMT-2 cultures at DIV8, 249±41 versus 227±22 nmol*mg prot-1 at DIV18, and 
258±30 versus 219±33 nmol*mg prot-1 at DIV28 (Figure 3A). Extracellular Cr levels were 
measured at 1.1±0.2 µM versus 1.2±0.1 µM in controls versus scAAV2/GAMT-2 cultures at 
DIV8, 20.6±0.3 versus 23.6±1.1 µM at DIV18, and 17.8±2.1 versus 25.3±3.2 µM at DIV28 
(Figure 3A). No significant difference in scAAV2/mismatched/scrambled cultures was 
observed. scAAV2/GAMT-2 cultures co-treated with 1mM Cr showed increase of both 
intracellular (508±27, 340±37 and 322±28 nmol*mg prot-1) and extracellular (533±34, 558±35 
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and 876±92 µM) Cr at DIV8, 18 and 28 respectively (Figure 3A). Co-treating cultures with Cr 
to prevent GAMT knockdown deleterious effect was performed at each medium renewal, Cr 
being measured prior to both medium change and next Cr co-treatment. 
 
As anticipated however, GAMT knockdown caused GAA accumulation which, analyzed by LC-
MS/MS, was increased intracellularly compared to controls at DIV8 (14.9±1.4 versus 2.8±0.7 
nmol*mg prot
-1
) and 18 (45.7±2.0 versus 4.0±1.2 nmol*mg prot-1) (Figure 3B). Extracellular 
GAA levels followed identical patterns (DIV8: 1.5±0.1 versus 0.5±0.1 µM; DIV18: 9.0±0.9 
versus 0.9±0.3 µM) (Figure 3B). At DIV28, GAA was barely detectable (intracellular: 0.6±0.1 
versus 0.7±0.1 nmol*mg prot-1; extracellular: 0.2±0.1 versus 0.2±0.1 µM). At all stages, no 
significant difference in scAAV2/mismatched/scrambled cultures was observed, except with 
DIV18 scAAV2/scrambled (slight GAA increase; data not shown). Interestingly, GAA 
accumulation was prevented with Cr co-treatment, with lower GAA levels than in controls 
(intracellular: 1.3±0.1 versus 2.8±0.7 nmol*mg prot-1 at DIV8; 1.2±0.5 versus 4.0±1.2 nmol*mg 
prot
-1
 at DIV18; extracellular: 0.4±0.1 versus 0.5±0.1 µM at DIV8; 0.4±0.1 versus 0.9±0.1 µM at 
DIV18). 
 
Partial GAMT deficiency generates axonal hypersprouting 
To investigate GAMT RNAi-induced consequences on developing neurons, we analyzed 
scAAV2/GAMT-2-transduced cultures for neuron-specific markers. The most striking 
observation was a specific axonal hypersprouting, shown by the strong increase of axonal-
enriched phosphorylated medium weight neurofilament (p-NFM; Figure 4A,B). Axonal bundles 
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augmentation was already observed at DIV8, but was most striking at DIV18, accompanied by 
axonal fibers and branches disorganization, developing in all directions including in aggregates 
center, otherwise peripherally-restricted (Figure 4A; see also Figure 2A). GAMT RNAi-induced 
total (3.6x) and phosphorylated (4.4x) NFM increase was confirmed by western blot (DIV18; 
Figure 4B). Axonal hypersprouting was also confirmed by the growth cone marker Growth-
Associated Protein 43 (GAP43) augmentation (1.8x at DIV18; Figure 4B). At DIV8 and 18, Cr 
co-treatment prevented axonal hypersprouting (Figure 4A,B). In neurons, GAA preferentially 
affected axons, as no significant effect was observed on Microtubule-Associated protein 2 
(MAP2; neuronal soma and dendrites; DIV18; Figure 4C). At DIV28, axonal hypersprouting 
was still present (p-NFM, Figure 4A; 1.9x GAP43 increase, Figure 4B). However, holes in 
aggregates centers were noticed (asterisks; Figure 4A), suggesting a secondary GAA-induced 
neuronal death illustrated by total (-46%) and phosphorylated (-40%) NFM decrease (Figure 
4B). At DIV28, Cr co-treatment also prevented GAMT RNAi-induced effects on neurons 
(Figure 4A). However, NFM levels were lower in Cr-co-treated cultures than controls (Figure 
4A,B), and at similar levels compared to scAAV2/mismatched/scrambled aggregates. In contrast 
to younger stages (DIV8,18), this suggests a viral effect on the long-term (see Figure 5 for 
similar effects on glial cells). We conclude that partial GAMT deficiency did not affect neuronal 
soma or dendrites but led to axonal hypersprouting that Cr co-treatment could prevent. 
 
Partial GAMT deficiency does not affect glial cells 
To investigate GAMT RNAi-induced glial cell disturbances, we analyzed scAAV2/GAMT-2-
transduced cultures for glial-specific markers. No GAMT RNAi-induced consequence on 
developing astrocytes was noticed at DIV8 and 18, confirmed by GFAP expression (Figure 
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5A,B). Oligodendocytes followed the same outcome, as validated by GalC and Myelin Basic 
Protein (MBP) expression (Figure 5C,E). Cr co-treatment did not affect GFAP or GalC (Figure 
5A-C). At DIV28, apart from the holes observed in aggregates centers, no GAMT RNAi-specific 
glial effect was observed (Figure 5A,C). However, as for neurons (Figure 4), a viral effect was 
seen at DIV28, with GFAP increase and MBP decrease in every scAAV2-transduced culture 
(Figure 5A,B,D,E), suggesting a long-term scAAV2-induced astrocyte reactivity and 
oligodendrocyte differentiation delay.  
 
Partial GAMT deficiency secondarily generates non-apoptotic cell death  
Axonal hypersprouting (DIV8, 18) and tissue loss (DIV28) (Figures 4,5) suggest that GAMT 
RNAi may alter natural brain cell death and drive tissue damage. We therefore investigated cell 
death by triple fluorescent co-staining of cleaved caspase-3 (apoptosis; red), TUNEL (all cell 
deaths; green) and DAPI (nucleus; blue) (Figure 6A). Apoptosis occurs in developing 3D brain 
cell aggregates as in immature CNS (Honegger and Monnet-Tschudi, 2001; Cagnon and 
Braissant, 2008) with higher cell death in younger compared to mature stages (red staining in 
control aggregates center) (Figure 6A). For all stages, we showed similar amounts of cell death 
in untreated and scAAV2/mismatched/scrambled-transduced cultures, thus excluding viral 
toxicity. Interestingly, scAAV2/GAMT-2-induced RNAi caused a significant natural apoptosis 
decrease, shown by cleaved caspase-3 reduction at DIV8, 18 and 28 (44%, 61% and 64%, 
respectively) which was prevented by Cr supplementation (Figure 6A,B). Moreover, cell death 
pattern was modified at DIV28 with a significant increase of TUNEL-only positive cells in 
scAAV2/GAMT-2-transduced aggregates centers (Figure 6A), suggesting a GAMT RNAi-
induced secondary induction of non-apoptotic cell death. Interestingly, these TUNEL-positive 
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cells surrounded the tissue loss observable as holes in scAAV2/GAMT-2-transduced aggregate 
centers (Figure 6A, asterisks) and could also be prevented by Cr supplementation. 
 
Direct exposure to GAA specifically resumes the effects of partial GAMT deficiency 
To investigate whether the observed GAMT RNAi-induced disturbances on axonal growth and 
cell death were specific of GAA accumulation, we exposed the 3D brain cell aggregates to GAA 
at 10 and 30 µM from DIV5 on, neighboring the extracellular GAA concentrations reached by 
scAAV2/GAMT-2 knockdown at DIV18 (see Figure 3). At DIV18, a dose-dependent axonal 
hypersprouting was observed under direct GAA exposure, while Cr supplementation prevented 
this effect for both 10 and 30 µM GAA (Figure 7A). Cell death analysis under direct GAA 
exposure revealed a similar effect as with scAAV2/GAMT-2 knockdown, showing at DIV18 a 
strong dose-dependent inhibition of apoptosis (cleaved caspase 3; red) and a complete inhibition 
of non-apoptotic cell death (TUNEL; green), which were also prevented by Cr co-treatment 
(Figures 7B). These results strongly suggests that GAA accumulation specifically and directly 
drives the effects on axonal growth and cell death in our model of partial GAMT deficiency in 
developing brain cells by RNAi.  
 
As GAA accumulates intracellularly under scAAV2/GAMT-2 knockdown while direct GAA 
application is extracellular, intra- and extracellular levels of GAA were measured at DIV8 and 
18 to verify that extracellularly-applied GAA at 10 and 30 µM was indeed taken up by brain 
cells (Figure 7C). 
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At DIV8, intracellular levels of GAA were increased under both 10 and 30 µM GAA exposure 
(3.3±0.7 and 20.2±1.8 versus 1.3±0.1 nmol*mg prot-1, p<0.01 and p<0.001 respectively) (Figure 
7C). GAA was not detectable in the medium of control cultures, while extracellular GAA levels 
under 10 and 30 µM GAA exposure were decreased to 0.53±0.12 and 3.91±0.43 µM respectively 
at DIV8 (Figure 7C). Similar results were obtained at DIV18. While intracellular GAA 
remained low under 10 µM GAA exposure (respectively 0.30±0.04 and 0.40±0.10 nmol*mg 
prot
-1
), it was increased under 30 µM GAA exposure (7.3±3.4 nmol*mg prot-1, p<0.01 as 
compared to controls) (Figure 7C). GAA was undetectable extracellularly in DIV18 control 
cultures, while extracellular GAA levels under 10 and 30 µM GAA exposure were decreased to 
undetectable and 2.55±0.86 µM respectively at DIV18 (Figure 7C). Our data confirm that 
externally-applied GAA is efficiently taken up by brain cells, even at much lower concentrations  
than previously published in the same system (10 / 30 µM versus 200 / 1000 µM) (Braissant et al 
2010). 
 
Altogether, our findings under direct GAA exposure confirm that the observed axonal 
hypersprouting and cell death disturbances are directly linked to the GAA accumulation caused 
by scAAV2/GAMT-2 knockdown in our partial GAMT deficiency model.  
 
GAA accumulation specifically alters GABAergic pathways  
As GAA activates GABAAR (Neu et al., 2002), we investigated whether its GAMT RNAi-
induced accumulation could disturb genes of the GABA-ergic neurotransmission pathway and 
whether Cr supplementation could prevent this effect. The expression of the presynaptic enzyme 
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Glutamate Decarboxylase (GAD, GABA synthesis) and of the postsynaptic receptor GABAAR 
were significantly increased in GAMT RNAi cultures (DIV18 and 28; Figure 8). In control 
conditions, GAD expression was restricted to neuronal cell bodies located in aggregate centers 
(Figure 8A, arrows), while under GAMT RNAi increased levels were also peripherally-located 
in the dense fiber zone. GABAAR was more widespread in control conditions (Figure 8B). 
However, as for GAD, GAMT RNAi induced a GABAAR increase in peripheral fibers, which 
was prevented by 1 mM Cr co-treatment (Figure 8). 
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Discussion 
 
Since its discovery (Stöckler et al., 1994; Schulze et al., 1997; Braissant, 2014; Stöckler-
Ipsiroglu et al., 2014), research on GAMT deficiency aimed at improving existing treatments (Cr 
supplementation; better means to decrease GAA). GAA accumulation in CNS is thought to cause 
its specific but poorly known pathophysiology. The only existing model, the Gamt
-/-
 mouse, 
while showing biochemical hallmarks (CNS Cr deficiency and GAA accumulation), does not 
present the severe neurological symptoms observed in patients (Renema et al., 2003; Schmidt et 
al., 2004; Tran et al., 2014). 
 
3D organotypic brain cell cultures in aggregates to model GAMT deficiency  
We chose 3D organotypic brain cell cultures to better understand GAMT deficiency in 
developing CNS (Honegger and Monnet-Tschudi, 2001; Braissant et al., 2002). They are derived 
from embryonic rat brains, grown in a chemically-defined medium without serum and Cr, 
develop in a stereotyped fashion (Figure 2A) and express AGAT, GAMT and SLC6A8 as the in 
vivo CNS (Braissant et al., 2001, 2008, 2010; Tachikawa et al., 2004; Lowe et al., 2014). To 
generate gene knockdown, we chose AAV vectors, known to cause little pathogenicity, offering 
many serotypes and cellular tropism and allowing post-mitotic cell transduction (Cearley et al., 
2008). In our cultures, scAAV2 targeted neurons, astrocytes and oligodendrocytes and induced 
GAMT deficiency by transducing a specific GAMT shRNA. No significant off-target effect 
could be observed (see Materials and Methods). 
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While scAAV2/GAMT efficiently drove RNAi, Gamt knock-down was incomplete (15% mean 
residual protein expression) and insufficient to cause Cr deficiency, but generated GAA 
accumulation, most probably by decrease of the Cr synthesis flux through partial GAMT activity 
in presence of normal AGAT expression. The mild GAA accumulation obtained in our model 
was comparable to GAA levels observed in GAMT-deficient patients cerebrospinal fluid 
(Almeida et al., 2004; Braissant and Henry, 2008; Stöckler et al., 2014). This allowed analysis of 
GAA-specific effects on brain cell development independently from Cr deficiency. Our study is 
the first demonstrating endogenous GAA accumulation by GAMT-deficient brain cells. The 
transient scAAV2-driven GAMT RNAi effect in our cultures (DIV18: maximal knock-down; 
DIV28: no more GAA accumulation) allowed demonstrating the potential irreversible impact of 
transient brain cell exposure to GAA. 
 
Our main finding was GAA-induced neuronal differentiation disturbance. Important axonal 
hypersprouting was observed early and peaked at DIV18, while no other morphological neuronal 
alterations were noticed. A decrease of apoptotic cells in aggregates centers, known to be 
neurons undergoing normal developmental cell death (Honegger and Monnet-Tschudi, 2001; 
Cagnon and Braissant, 2008), accompanied axonal hypersprouting, suggesting a GAA-induced 
dysregulation disengaging neurons from apoptosis and overstimulating them to elongate axons. 
The specificity of the GAA-induced deleterious effects on brain cell development under GAMT 
knockdown was confirmed by the strict reproducibility of these effects under direct GAA 
exposure. 
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No specific GAA-linked consequence was observed on glial cells. However, a non-specific long-
term viral effect was seen at DIV28 through astrocytic reactivity (GFAP increase) and slowing of 
oligodendrocytes differentiation (stable GalC but MBP decrease). 
 
Relevance to GAMT deficiency and potential mechanisms 
GAMT deficiency results in intellectual disability/developmental delay, speech acquisition 
impairment, autistic behavior, severe epilepsies and movement disorders (Stöckler-Ipsiroglu et 
al., 2014). During normal development, synaptogenesis requires initial neuronal apoptosis 
inhibition, exuberant axonal growth, and postsynaptic neuronal targeting followed by selective 
axonal pruning (Low and Cheng, 2006; Diez et al., 2012). This final step occurs through 
neurotrophin support deficiency from post-synaptic neurons, which secondarily induces neuronal 
autophagic death (McKnight et al., 2012). Similar but exaggerated mechanisms occur in brain 
pathologies including epilepsies and neurodegenerative disorders (Alzheimer’s and Parkinson’s 
diseases, neurometabolic disorders) which may exhibit aberrant axonal growth followed by 
neuronal autophagy, behavioral consequences, cognitive decline and seizures (Yan et al., 2012a, 
2012b; Ebrahimi-Fakhari et al., 2014). Our partial GAMT-deficient cultures exhibited identical 
patterns with primary axonal hypersprouting paralleled by apoptosis decrease. Secondarily, while 
GAP43 was still overexpressed and apoptosis still diminished, non-apoptotic cell death was 
induced, probably through autophagy in neurons with GAA-induced superfluous axons and 
lacking post-synaptic neurotrophins. 
 
Axonal hypersprouting may occur through GAA-induced slowing of Na
+
/K
+
-ATPase (Zugno et 
al., 2004), leading to increased intracellular Ca
++
 triggering augmented expression (shown here) 
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and overactivation of Ca
++
-dependent GAP43 (Dunican and Doherty, 2000), known to 
participate in axonal sprouting (Aungst et al., 2013). 
 
GAMT RNAi led to expression alteration of genes of the GABA-ergic neurotransmission 
pathway. Cr and GAA are known to affect GABA-ergic neurotransmission as partial agonists or 
antagonists on post-synaptic GABAAR (De Deyn et al., 1991; Neu et al., 2002; Cupello et al., 
2008). We confirmed that GAA accumulation disturbs post-synaptic GABAAR-expressing 
neurons, and demonstrate for the first time that their pre-synaptic GAD-expressing GABA-ergic 
partners appear affected. Thus, severe epilepsies in GAMT deficiency may not only be caused by 
direct GAA action on GABAAR, but also by aberrant re-modeling of GABA-ergic circuitry 
through axonal hypersprouting, which was shown to play a role in epilepsy emergence and 
compensatory mechanisms balancing excitatory neurotransmission (Bausch, 2005; Buckmaster 
and Wen, 2011). GAA accumulation, by direct GABAAR disturbances or by axonal 
hypersprouting followed by neuronal autophagy, may also affect the recently proposed role of Cr 
as neurotransmitter (Almeida et al., 2006; Peral et al., 2010; van de Kamp et al., 2013). 
 
Diagnosis of GAMT deficiency and neonatal screening 
GAMT deficiency is diagnosed in patients with intellectual disability/developmental delay or 
severe seizures once CNS Cr deficiency has been demonstrated by 
1
H-MRS together with 
elevated GAA in blood or urine (Stöckler-Ipsiroglu et al., 2014). Every patient diagnosed so far 
showed negligible (0-4%) residual GAMT activity (Mercimek-Mahmutoglu et al., 2006, 2014). 
Our findings suggest that GAMT activity must be negligible to cause CNS Cr deficiency, as 15% 
residual expression did not generate Cr deficiency. However, GAMT residual expression was 
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insufficient to maintain normal GAA levels, and accumulated GAA without Cr deficiency was 
sufficient to produce irreversible effects on brain cells. Our results suggest that some patients 
with residual GAMT activity may be missed, escaping diagnosis due to lack of CNS Cr 
deficiency. Recent proposals for GAMT deficiency entry in neonatal screening programs by 
measure of GAA on dried blood spots (Mercimek-Mahmutoglu et al., 2012; El-Gharbawy et al., 
2013; Pasquali et al., 2014) would therefore also help identify those patients with significant 
residual GAMT activity and allow their pre-symptomatic treatment (Schulze et al., 2006). This 
may also allow the detection of altered, toxic levels of GAA independently of GAMT deficiency, 
as recently observed for example in arginase deficiency (Amayreh et al., 2014). 
 
Prevention of GAA toxicity by creatine supplementation 
Our second striking result was the prevention of all observed GAA deleterious effects by Cr 
supplementation, despite GAMT deficiency. Cr supplementation, paralleled to scAAV2/GAMT-
2 transduction, prevented axonal hypersprouting, natural apoptosis decrease, and secondary 
increase of non-apoptotic cell death. It also prevented GABA-ergic disturbances. While other 
neuroprotective mechanisms by Cr (Gualano et al., 2010) cannot be excluded, prevention of 
GAA effects probably occurred through negative feedback regulation of the first enzyme of Cr 
synthesis, AGAT, leading to GAA measures below control levels. AGAT feedback inhibition by 
Cr, though already known in kidney cells (Takeda et al., 1992), has never beforehand been 
demonstrated in AGAT-expressing brain cells (Braissant et al., 2008, 2010). The prevention of 
both GAA accumulation and its toxic effects by Cr supplementation despite GAMT deficiency, 
together with the prevention of the same toxic effects by Cr supplementation under direct 
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exposure to GAA, demonstrates the direct involvement of GAA in axonal hypersprouting and 
disturbed brain cell death in our model of partial GAMT deficiency by RNAi. 
 
GAMT deficiency treatment requires life-long high Cr doses due to low BBB permeability for Cr 
(Braissant, 2012; Stöckler-Ipsiroglu et al., 2014). Associated GAA-lowering strategies (ornithine 
supplementation and arginine restriction; Schulze et al., 2001) strongly decrease plasma and 
cerebrospinal fluid GAA, but brain levels remain 10 times above normal values (Stöckler-
Ipsiroglu et al., 2014). Our work suggests that finding new ways to increase Cr transport efficacy 
through BBB may correct GAA to control levels in GAMT-deficient CNS and significantly 
improve the disease outcome. One possibility would be the induction of the SLC6A8 transporter 
in the astrocytic feet surrounding BBB, which would greatly increase BBB permeability for Cr.  
 
Conclusions 
We have shown in 3D organotypic brain cell cultures that GAMT deficiency with significant 
residual enzymatic activity does not lead to Cr deficiency but generates sufficient GAA to 
irreversibly affect developing CNS. GAA primarily impacted neurons by axonal hypersprouting 
and apoptosis inhibition, followed by secondary non-apoptotic cell death induction. Future work 
will aim at better characterizing signaling pathways involved, disturbances in neurotransmission 
and cell death (apoptosis versus autophagy or necrosis). We could characterize some of the brain 
GAA-specific effects independently from Cr deficiency. Our results should stimulate the search 
for GAMT-deficient patients with significant residual GAMT activity, escaping Cr deficiency 
diagnosis but presenting symptoms of GAMT deficiency. These patients should be identified 
through newly proposed programs of neonatal screening by GAA measurement. Our work 
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finally suggests that facilitating Cr crossing through BBB may help normalizing brain GAA 
levels and further improve the outcome of GAMT deficiency. 
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Figure legends 
 
Figure 1: AAV2-transduced GAMT deficiency in 3D organotypic developing brain cell 
cultures. (A) The three sequences selected for GAMT RNAi, with their respective location on 
the rat Gamt gene ORF. Ctrl-2 mismatched and scrambled are the GAMT-2 siRNA-derived 
negative controls. (B) Dual luciferase assay for selection of the best GAMT shRNA. Co-
transfection of ROC cells with pRNAT-CMV3.2/Neo/GAMT-1/2/3/empty and psiCHECK-
GAMT. GAMT-2 shRNA led to the best knockdown. (C) GAMT protein expression in ROC cell 
monolayer after pRNAT-CMV3.2/Neo/GAMT-2 transfection or AAV2/GAMT-2 transduction 
(MOI 300). GAMT knockdown specificity was tested by transfection with empty vector or the 
negative controls pRNAT-CMV.3.2/Neo/mismatched/scrambled. GAMT-2 shRNA drove a 
specific GAMT protein knockdown, and AAV2 viruses efficiently transduced the RNAi effect. 
Western blotting experiment normalized with -tubulin. (D) GAMT protein expression in 3D 
organotypic brain cell cultures at DIV8 (top), DIV18 (middle) and DIV28 (bottom) after 
scAAV2/GAMT-2 transduction (MOIs 100/300/1000). Mismatched and scrambled negative 
controls were used to evaluate RNAi specificity (MOI 1000). Western blotting experiments 
normalized with actin. (E) Single point comparative expression of GAMT protein at DIV8, 18 
and 28 in a representative culture transduced by scAAV2/GAMT-2 (MOI 1000). The highest 
GAMT expression and the strongest GAMT knockdown were observed at DIV18 (MOI 1000, 
n=1). Western blotting experiment normalized with actin. Western blotting data presented in 
B,C,D: mean ± s.e.m (n=6 in 1 out of 5 representative experiments). *P<0.05, **P<0.01, 
***P<0.001. 
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Figure 2: 3D organotypic brain cell cultures transduced by EGFP-expressing scAAV2. (A) 
Normal development schemes of 3D organotypic brain cell cultures. Aggregates at DIV8, 18 and 
28 are described, at low and high magnification. Cultures develop with neurons, astrocytes and 
oligodendrocytes in a stereotyped manner. Neuronal soma are located in aggregate centers, and 
mixed with numerous astrocytes and rare oligodendrocytes. Neurons differentiate by sending 
processes and particularly axons (red lines, including growth cone triangles) at the periphery 
where privileged synapses are established (aggregate periphery delimited in enlarged boxes by 
the external continuous and the dotted black lines). The external cell layer of aggregates is 
essentially composed of astrocytes and few oligodendrocytes. The detailed description of this 
culture system has been extensively explained (Honegger and Monnet-Tschudi, 2001; Braissant 
et al., 2002; Cagnon and Braissant, 2008). (B) EGFP native fluorescence in scAAV2-transduced 
brain cells in whole aggregates (line 1) or aggregate cryosections (lines 2-5) at DIV8 (column 1), 
18 (column 2) and 28 (column 3), showing the increase of EGFP in both level of expression and 
number of positive cells. scAAV2 targeted neurons (line 3; co-labeling with NeuN), astrocytes 
(line 4; co-labeling with GFAP) and oligodendrocytes (line 5; co-labeling with GalC). Column 4: 
higher magnifications of the boxed regions in their respective lines. Scale bars: 100 μm (columns 
1-3) and 20 µm (column 4). MOI: 1000 for every infected culture. 
 
Figure 3: GAA accumulation but no Cr deficiency under partial GAMT deficiency. 
Intracellular (black) and extracellular (grey) levels of Cr (A) and GAA (B) in control or 
scAAV2/GAMT-2-transduced cultures, with or without Cr supplementation (1 mM). While the 
awaited accumulation of GAA was observed in scAAV2/GAMT-2-transduced aggregates, no Cr 
deficiency could be observed under partial GAMT deficiency. Interestingly, GAA accumulation 
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was completely prevented by Cr supplementation in scAAV2/GAMT-2-transduced cultures. 
Mean ± s.e.m (n=6 in 1 out of 3 representative experiments); intracellular: *P<0.05, **P<0.01, 
***P<0.001; extracellular: 
+
P<0.05, 
++
P<0.01, 
+++
P<0.001. 
 
Figure 4: Partial GAMT deficiency leads to axonal hypersprouting. (A) 
Immunofluorescence for p-NFM in axons of control or scAAV2/GAMT-
2/mismatched/scrambled-transduced cultures, with or without Cr supplementation (1 mM). 
Panels on the right: higher magnifications of boxed regions highlighted in the DIV18 column; 
aggregate periphery delimited by the external continuous and the dotted lines. GAMT RNAi 
induced axonal hypersprouting which occurred peripherally and in aggretate centers 
(DIV8,18,28). Axonal hypersprouting was prevented by Cr co-treatment (1 mM). 
scAAV2/GAMT-2-transduction caused tissue loss at DIV28, observable as holes (asterisks). At 
DIV28, except for the specific axonal hypersprouting still observable in GAMT RNAi 
aggregates, a non-specific viral effect was seen in every other scAAV2-transduced conditions 
(GAMT RNAi + Cr, mismatched, scrambled) which led to p-NFM decrease as compared to 
controls. (B) Expression of total NFM (grey), p-NFM (black) and GAP43 in DIV18 and 28 
cultures. NFM and GAP43 increase was specific at DIV18, and prevented by Cr co-treatment. 
The effect was still observable for GAP43 at DIV28, while scAAV2/GAMT-2-transduction with 
and without Cr co-treatment showed NFM and p-NFM decrease. Western blotting experiments 
normalized with actin. (C) Immunofluorescence for MAP2 in DIV18 cultures. No change in 
MAP-2 expression was observed. MOI: 1000 for every infected culture. Scale bars: 100 μm 
(except enlarged boxes in a: 10 µm). Histological data in A,C: evaluation of n=3 in 1 out of 4 
representative experiments; western blotting data in B: mean ± s.e.m (n=3 in 1 out of 4 
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representative experiments); total NFM: *P<0.05, **P<0.01, ***P<0.001; p-NFM: 
+
P<0.05, 
++
P<0.01, 
+++
P<0.001. 
 
Figure 5: Partial GAMT deficiency does not affect glial cells. (A) Immunofluorescence for 
GFAP in astrocytes of control or scAAV2/GAMT-2/mismatched/scrambled-transduced cultures, 
with or without Cr supplementation (1 mM). GAA accumulation did not affect GFAP expression 
(DIV8,18). GAMT RNAi-specific tissue loss was observable as holes (DIV28; asterisks). A non-
specific viral effect was seen at DIV28 only, leading to GFAP increase. (B) Western blotting 
analysis of GFAP in control or scAAV2/GAMT-2-transduced cultures, with or without Cr 
supplementation. As in A, no change in GFAP expression could be observed at DIV18, while at 
DIV28, all scAAV2/GAMT-2-transduced aggregates showed GFAP increased expression. (C) 
Immunofluorescence for GalC in oligodendrocytes of control or scAAV2/GAMT-2-transduced 
cultures, with or without Cr supplementation. GAMT RNAi did not affect GalC or the number of 
oligodendrocytes at either stage. (D) Immunofluorescence for MBP in control or 
scAAV2/GAMT-2/mismatched/scrambled-transduced cultures, with or without Cr 
supplementation (DIV28). Aggregate periphery delimited by the external continuous and the 
dotted lines. As in A, a non-specific viral effect was observed, showed by MBP decrease. (E) 
Western blotting analysis of MBP in control or scAAV2/GAMT-2-transduced cultures, with or 
without Cr supplementation (DIV18,28). No change in MBP expression could be observed at 
DIV18, while at DIV28 all scAAV2/GAMT-2-transduced aggregates showed MBP decrease. 
Western blotting experiments normalized with actin. MOI: 1000 for every infected culture. Scale 
bar: 100 μm. Histological data in A,C,D: evaluation of n=3 in 1 out of 4 representative 
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experiments; western blotting data in B,E: mean ± s.e.m (n=3 in 1 out of 4 representative 
experiments); *P<0.05, **P<0.01. 
 
Figure 6: Partial GAMT deficiency primarily decreases normal developmental apoptosis, 
and secondarily induces non-apoptotic death of brain cells. (A) Fluorescent co-labeling of 
cell nuclei (DAPI; blue), whole dying (TUNEL; green) and apoptotic (cleaved caspase-3; red) 
cells in control or scAAV2/GAMT-2/mismatched/scrambled-transduced cultures, with or 
without Cr supplementation (1 mM). Aggregate periphery delimited by the external continuous 
and the dotted lines. At every stage, GAMT RNAi induced a decrease of naturally-occurring 
apoptosis (red), especially in aggregate centers (right of the dotted line). As expected, the 
number of naturally occurring apoptotic cells in control aggregates was lower in the more mature 
DIV28 stage than at DIV8 or 18. At DIV28, a specific GAMT RNAi-induced secondary increase 
in non-apoptotic dying cells was observed in aggregate centers (green-only TUNEL, without co-
labeling by red activated caspase-3). These TUNEL-labeled dying cells at DIV28 surrounded the 
same tissue alterations illustrative of massive cell death as shown in Figures 3A and 4A, and 
observable as holes (asterisks). These specific GAMT RNAi effects on cell death (both apoptotic 
and non-apoptotic) were prevented by Cr co-treatment. (B) Western blotting analysis of cleaved 
caspase-3 in control or scAAV2/GAMT-2-transduced cultures, with or without Cr 
supplementation. At every stage, cleaved caspase-3 was significantly decreased in 
scAAV2/GAMT-2-transduced cultures and Cr co-treatment prevented this effect. Western 
blotting experiments normalized with actin. MOI: 1000 for every infected culture. Scale bar: 100 
μm. Histological data in A: evaluation of n=3 in 1 out of 4 representative experiments; western 
blotting data in B: mean ± s.e.m (n=3 in 1 out of 4 representative experiments); **P<0.01. 
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Figure 7: Direct exposure to GAA resumes the effect of scAAV2-transduced partial GAMT 
deficiency, generating axonal hypersprouting and inhibiting apoptosis. Immunofluorescence 
analysis of p-NFM (A) and cleaved caspase 3 (B), as well as TUNEL labeling (B), in DIV18 
controls and cultures exposed to 10 or 30 µM GAA, with or without Cr supplementation (1 mM). 
At DIV18, direct GAA exposure generated a dose-dependent axonal hypersprouting, as well as 
inhibition of apoptosis. Both GAA-induced effects were prevented by Cr co-treatment. Intra- and 
extracellular measure of GAA (C) in DIV8 and DIV18 controls and cultures exposed to 10 or 30 
µM GAA. GAA-exposed cultures were able to take up GAA. Scale bar: 100 μm (except enlarged 
boxes in A: 10 μm). Histological data in A,B: evaluation of n=3 in 1 out of 4 representative 
experiments. Data in C: mean ± s.e.m (n=3 in 1 out of 3 representative experiments); 
intracellular: **P<0.01, ***P<0.001. 
 
Figure 8: GAA accumulation under partial GAMT deficiency alters gene expression in 
GABA-ergic neurotransmission pathways. Immunofluorescence and western blotting analysis 
of GAD (A) and GABAAR (B) in control and scAAV2/GAMT-2-transduced cultures, with or 
without Cr supplementation (1 mM). Increased GAD and GABAAR expression was observed in 
the peripheral zone of scAAV2-GAMT-2-transduced and GAA-exposed aggregates at DIV18 
and 28. This effect was prevented by Cr co-treatment. Aggregate periphery delimited by the 
external continuous and the dotted lines; positive neuronal cell bodies indicated by arrows. MOI: 
1000 for every infected culture. Scale bar: 100 μm. Western blotting experiments normalized 
with actin. Histological data in A,B: evaluation of n=3 in 1 out of 4 representative experiments; 
western blotting data in A,B: mean ± s.e.m (n=3 in 1 out of 4 representative experiments); 
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